Market Place
Sourcing Support
Merck`s HIV Combo Matches Gilead`s Biktarvy In Phase 3 Test
21 Nov 2025 //
BUSINESSWIRE
Merck`s HIV Combo Matches Gilead`s Biktarvy In Phase 3 Test
19 Nov 2025 //
BUSINESSWIRE
Galapagos Urged By Gilead To Avoid Extinction
19 Nov 2025 //
FIERCE BIOTECH
Gilead Partners For First Shipments Of Twice-Yearly Lenacapavir
18 Nov 2025 //
BUSINESSWIRE
Before Glp-1S, A Great Pricing Battle Played Out In Hep C Market
18 Nov 2025 //
BIOSPACE
Gilead`s Bictegravir, Lenacapavir Tablet Meets Mark In Phase 3
13 Nov 2025 //
BUSINESSWIRE
J&J, Legend Pull ASH Paper Comparing Carvykti Against Rival CAR-T
12 Nov 2025 //
FIERCE PHARMA
AHF`s Mobile Billboard Calls Out Gilead`s Greed At Pharma Summit
10 Nov 2025 //
BUSINESS WIRE
Gilead Provides Update On Phase 3 ASCENT-07 Study
07 Nov 2025 //
BUSINESSWIRE
Gilead Livdelzi Shows Sustained Efficacy And ALP Reduction In PBC
07 Nov 2025 //
BUSINESSWIRE
Gilead Sciences To Present At Upcoming Investor Conferences
04 Nov 2025 //
BUSINESS WIRE
Gilead And Kite Show Progress In Blood Cancer Cell Therapy Data
03 Nov 2025 //
BUSINESSWIRE
Gilead Sciences Receives 2025 Prix Galien USA Award For Yeztugo
31 Oct 2025 //
BUSINESSWIRE
HOOKIPA Pharma Completes Sale Of HBV & HIV Assets To Gilead
31 Oct 2025 //
GLOBENEWSWIRE
Gilead Lifts Guidance on Prep Launch Despite Cell Therapy Woes
31 Oct 2025 //
FIERCE PHARMA
Gilead Sciences Announces Third Quarter 2025 Financial Results
30 Oct 2025 //
BUSINESSWIRE
AHF, And 100 Organizations Stop Gilead`s Drug Price Hikes
29 Oct 2025 //
BUSINESSWIRE
Gilead to Present Livdelzi and Bulevirtide Efficacy Data
23 Oct 2025 //
BUSINESSWIRE
80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
21 Oct 2025 //
BUSINESSWIRE
Gilead`s Trodelvy Cuts Breast Cancer Risk by 38% in Trial
20 Oct 2025 //
REUTERS
Kite Puts $1.64B On Line For Pregene`s In Vivo CAR-T Deal
20 Oct 2025 //
FIERCE BIOTECH
Gilead To Present Latest Virology Data At IDWEEK 2025
19 Oct 2025 //
BUSINESSWIRE
ESMO: Datroway Data Edge Out Trodelvy In First TROP2 Face-Off
19 Oct 2025 //
FIERCE PHARMA
GSK Tout Study Showing Tolerability Edge for Its Long-Acting PrEP
15 Oct 2025 //
FIERCE PHARMA
Gilead, Kite To Revolutionize Cancer Care With ESMO 2025 Data
14 Oct 2025 //
INDPHARMAPOST
Gilead, Kite Showcase Cancer Care Transformation At ESMO 2025
13 Oct 2025 //
BUSINESSWIRE
Gilead, Arcus Keep TIGIT Dream Alive With 27-Month OS Data
13 Oct 2025 //
FIERCE BIOTECH
Gilead Sciences To Report Q3 2025 Financial Results On October 30
09 Oct 2025 //
BUSINESSWIRE
Gilead Inks Biktarvy Settlements With 3 Generic Drug Makers
07 Oct 2025 //
FIERCE PHARMA
Hanmi`s Oral Delivery Platform Compound Licensed To Gilead
29 Sep 2025 //
PR NEWSWIRE
Gilead Pumps Up Virology Pipeline With Drug Transporter Deal
29 Sep 2025 //
PR NEWSWIRE
TWN Urges Universal $40/year Access To Generic Lenacapavir
26 Sep 2025 //
PHARMABIZ
Gilead Invests $6.5M In STEM Education In San Francisco Bay
25 Sep 2025 //
CONTRACTPHARM
Lupin Gets Tentative FDA Nod For Biktarvy Tablets
25 Sep 2025 //
EXPRESSPHARMA
CDC Strongly Recommends Gilead`s HIV PrEP Yeztugo
19 Sep 2025 //
FIERCE PHARMA
Study: One-Third of Trial Data May Be Unnecessary
19 Sep 2025 //
FIERCE BIOTECH
Marengo Therapeutics Expands STARt-002 Trial to Phase 2
18 Sep 2025 //
PR NEWSWIRE
Fangzhou Wins Gilead ‘Award of Excellence’ for AI Management
17 Sep 2025 //
GLOBENEWSWIRE
Gilead Beats Whistleblower Lawsuit over Hepatitis C drugs
15 Sep 2025 //
REUTERS
Gilead Launches New Primary Biliary Cholangitis Campaign
10 Sep 2025 //
FIERCE PHARMA
Gilead Sciences Partners with Veeva Vault CRM
10 Sep 2025 //
PRESS RELEASE
Vyome Holdings Bolsters Team for Pivotal Trial Studies
09 Sep 2025 //
PHARMAWEB
Xilio Starts Ph 2 XTX301 Trial, Hits $17.5M Gilead Milestone
09 Sep 2025 //
GLOBENEWSWIRE
IDEAYA Reveals Ph 1/2 Trial Data of IDE397 & Trodelvy in Cancer
08 Sep 2025 //
PR NEWSWIRE
US Plans to Bring Gilead HIV Drug to Market
05 Sep 2025 //
REUTERS
Gilead Urges HIV Patients to `Choose U` in Campaign
04 Sep 2025 //
FIERCE PHARMA
Gilead Starts Construction on Development & Manufacturing Center
04 Sep 2025 //
CONTRACTPHARMA
Gilead Partners PEPFAR for Biannual Lenacapavir Supply
04 Sep 2025 //
BUSINESSWIRE
Gilead breaks ground on production hub as part of $32B US outlay
04 Sep 2025 //
FIERCE PHARMA
Gilead Breaks Ground on Production Hub as Part of $32B US Outlay
03 Sep 2025 //
FIERCE PHARMA
Gilead`s Kite Erodes $2.3B Shoreline Cell Therapy Deal
03 Sep 2025 //
FIERCE BIOTECH
EU approves Gilead`s new injection for preventing HIV
27 Aug 2025 //
REUTERS
Gilead Sciences`s Yeytuo Receives Approval in Europe
25 Aug 2025 //
EMA
CVS Denies Coverage for Gilead`s Biannual PrEP Drug Yeztugo
21 Aug 2025 //
FIERCE PHARMA
Gilead Sciences to Attend Future Investor Conferences
20 Aug 2025 //
BUSINESSWIRE
Gilead Reports 7% Sales Decline for CAR-T`s Yescarta, Tecartus
12 Aug 2025 //
FIERCE PHARMA
Gilead Sciences`s Hepcludex Receives Approval in Canada
08 Aug 2025 //
FDA
Gilead Ends Last MASH Program, Drops 2 Cancer Assets
08 Aug 2025 //
FIERCE BIOTECH
Gilead`s CAR-Ts Yescarta, Tecartus Sales Drop by 7%
08 Aug 2025 //
FIERCE PHARMA
Gilead Confident in PrEP Despite Task Force Uncertainty
08 Aug 2025 //
BIOSPACE
